Showing 21-30 of 574 results for "".
- Regulations Needed to Reduce Rates of Nickel Allergic Contact Dermatitishttps://practicaldermatology.com/news/regulations-needed-to-reduce-rates-of-nickel-allergic-contact-dermatitis/2460364/The U.S. government must start regulating nickel in clothing and jewelry to reduce nickel allergic contact dermatitis reactions, according to a new American Academy of Pediatrics policy statement. Nickel is now the No. 1 allergen nationwide in all age groups, and the number of children who test po…
- Foamix Update: Nine Trials in Five Postershttps://practicaldermatology.com/news/foamix-update-nine-trials-in-five-posters/2460192/Results from nine clinical trials of Foamix Pharmaceutical investigational products will be presented in five posters at the 39th Annual Fall Clinical Dermatology Conferencein Las Vegas. Findings relate FMX101 for the treatment of moderate-to-severe acne and FMX103 for the treatment of moderate-to-…
- Melanoma Research Alliance Awards Inaugural Cohort of Nine Dermatology Research Fellowshttps://practicaldermatology.com/news/melanoma-research-alliance-awards-inaugural-cohort-of-nine-dermatology-research-fellows/2460139/In recognition of the critical role dermatologists can play in the prevention and early detection of melanoma, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, announced the inaugural cohort of nine dermatology research fellows. The fellows, which include M…
- ISDIN Launches Melatonik Nighttime Serumhttps://practicaldermatology.com/news/isdin-launches-melatonik-nighttime-serum/2457577/ISDIN's Melatonik nighttime serum formulated with melatonin, bakuchiol (a natural antioxidant with retinol-like properties) and Vitamin C, is now available. It was developed to help skin recover from the day and prepare it to fight the stresses of tomorrow, ISDIN says. Melatonik stimulates the sk…
- RealSelf Survey: More than 1 in 3 US Adults are Considering Nips/Tuckshttps://practicaldermatology.com/news/realself-survey-more-than-1-in-3-us-adults-are-considering-nipstucks/2457591/One in three adults (37 percent) in the US are considering at least one cosmetic treatment in the next 12 months, with significantly more considering nonsurgical procedures (34 percent) than surgical ones (24 percent), according to the RealSelf Aesthetics Interest Survey. Fully four in five (80 pe…
- Cynosure to Distribute Porter Instrument's Nitrous Oxide and Oxygen System in Aesthetics Markethttps://practicaldermatology.com/news/cynosure-to-distribute-porter-instruments-nitrous-oxide-and-oxygen-system-in-aesthetics-market/2457649/Hologic, Inc.'s Cynosure division has penned a deal with Porter Instrument, a business unit of Parker Hannifin Corporation, for distribution rights in the United States and Canada to Porter Instrument's nitrous oxide and oxygen system, Nitronox™. Cynosure is the first medical aesthetic manufacturer…
- Research on Nitric Oxide-Releasing Nanoparticles Reveals Promising Skin Infection Treatmenthttps://practicaldermatology.com/news/research-on-nitric-oxide-releasing-nanoparticles-reveals-promising-skin-infection-treatment/2458095/George Washington University (GW) researchers have found that topically applied nitric oxide-releasing nanoparticles (NO-np) are a viable treatment for deep fungal infections of the skin caused by dermatophytes, for which the current standard of care is treatment with systemic antifungals.
- Novan Forms New Advisory Council Focused on Nitric Oxide Technologies in Dermatologyhttps://practicaldermatology.com/news/novan-forms-new-advisory-council-focused-on-nitric-oxide-technologies-in-dermatology/2458228/Novan, Inc. has formed an Advisory Council comprised of key opinion leaders with broad expertise in dermatology. These leading physicians will provide medical advice and drug-development insight to the Company’s senior leadership team and board of directors. The Advisory Council will be chaired by…
- Orphan Drug Designation Granted to Nintedanib for Systemic Sclerosishttps://practicaldermatology.com/news/orphan-drug-designation-granted-to-nintedanib-for-systemic-sclerosis/2458441/The European Commission (EC) and the FDA have granted Orphan Drug Designation to Boehringer Ingelheim's nintedanib for the treatment of systemic sclerosis (SSc, also known as scleroderma), including the associated interstitial lung disease (SSc-ILD). SENSCIS™, the largest trial to date in this dis…
- Nivolumab Approved in Combination with Ipilimumabhttps://practicaldermatology.com/news/nivolumab-approved-in-combination-with-ipilimumab/2458859/The FDA has granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type unresectable or metastatic melanoma. The clinical trial that supported approval randomized (2:1) 142 patients…